Table 1 Baseline characteristics and demographics of ravulizumab-treated patients enrolled in REVEAL

Age, years, median (IQR)

34 (28–38)

Female, n (%)

15 (54%)

Ethnicity, n (%)

 Hispanic or Latino

3 (11%)

 Not Hispanic or Latino

25 (89%)

Race, n (%)

 White

24 (86%)

 Black or African American

2 (7.1%)

 Asian

1 (3.6%)

 Other

2 (7.1%)

Body mass index, kg/m², median (IQR)

26.2 (23.3–28.8)

Highest level of education, n (%)

 High school graduate, diploma, or the equivalent

1 (3.6%)

 Some college or no degree

6 (21%)

 College graduate, associate, or bachelor’s degree

8 (29%)

 Graduate degree

12 (43%)

 Doctorate degree

1 (3.6%)

Annual household income, n (%)

 Less than $25,000

4 (14%)

 $25,000–34,999

1 (3.6%)

 $35,000–49,999

3 (11%)

 $50,000–74,999

2 (7.1%)

 $75,000–99,999

7 (25%)

 $100,000–149,999

7 (25%)

 $150,000 or more

2 (7.1%)

 Prefer not to answer

2 (7.1%)

Age at symptom onset, years, median (IQR)

27 (21–30)

Age at diagnosis, years, median (IQR)

28 (21–34)

Clone size, %, median (IQR)

69 (35–94)

Hemoglobin level, g/dl, median (IQR)

11.15 (10.60–12.55)

Lactate dehydrogenase level, U/L, median (IQR)

226 (187–266)

Blood transfusions in the past 3 months, n (%)

 0

27 (96%)

 1–10

1 (3.6%)

 11–20

0 (0%)